Nucala (Mepolizumab)

Mepolizumab, the active ingredient in Nucala, is a monoclonal antibody (IL-5 antagonist) presented as a solution for injection for subcutaneous use. It treats severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and chronic rhinosinusitis with nasal polyps in patients who meet specific clinical criteria.

GNH USA supplies Nucala as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nucala is a biologic that targets the IL‑5 pathway, a key driver of eosinophilic inflammation in several respiratory and systemic disorders. - Severe eosinophilic asthma: reduces exacerbations and improves lung function. - Eosinophilic granulomatosis with polyangiitis (EGPA): helps achieve remission and lowers oral steroid requirements. - Chronic rhinosinusitis with nasal polyps: decreases polyp size and relieves sinus symptoms.

Common side effects are generally mild and related to the injection process or systemic exposure.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Headache: mild to moderate intensity. - Fatigue: transient tiredness. - Nasopharyngitis: upper respiratory tract infection symptoms.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hypersensitivity reactions: including rash, urticaria, or angioedema. - Immune‑mediated conditions: such as vasculitis or serum sickness‑like reactions.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks. - Parasitic infection screening: assess for helminth infections before treatment. - Hypersensitivity monitoring: observe for signs of allergic reactions during and after injection. - Eosinophil count assessment: confirm elevated eosinophils as a prerequisite for use. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mepolizumab may interact with other agents that affect immune function or vaccine efficacy.

Major Interactions (Avoid): - Live attenuated vaccines: increased risk of infection; avoid concurrent administration. - Other IL‑5 targeting biologics: concurrent use may amplify immunosuppression.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may alter infection risk; monitor patient closely. - Immunosuppressive agents (e.g., azathioprine, methotrexate): observe for additive immunosuppression. - Non‑live vaccines: efficacy may be reduced; assess immune response when needed.